JPRN-jRCT2080220891未知1 期
A Phase I, Open Label, Single-centre Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 Administered Orally to Japanese Patients With Advanced Solid Tumours
适应症
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Japanese patients with advanced solid tumors for which suitable effective standard treatment does not exist or is no longer effective
- •- Relatively good overall health other than cancer
排除标准
- •- Poor bone marrow function (not producing enough blood cells)
- •- Poor liver or kidney function
- •- Serious concomitant illness
研究者
相似试验
已完成
1 期
A Phase 1 Single-Center, Open-Label Study to Evaluate the Safety and Pharmacokinetics of a Candidate Topical Antimicrobial (NEO101) among Healthy Adult MeOpen-label safety pharmacokinetic study in healthy adult men of topical antimicrobial being developed for the indication of nasal carriage of Staphylococcus aureus.Infection - Studies of infection and infectious agentsACTRN12607000260426eosil, Inc5
已完成
1 期
A Study to Evaluate Single Doses of Dihydroergotamine Mesylate Inhalation Powder and Dihydroergotamine Mesylate Intravenous in Healthy Adult SubjectsACTRN12623001201662Syneos Health New Zealand Ltd28
进行中（未招募）
1 期
A phase I, open-label, single-centre study to evaluate the absorption, distribution, metabolism and excretion (ADME) of oral [14C]-ibrexafungerp in healthy male subjects after repeat dosingFungal diseaseInfections and InfestationsISRCTN51111674Scynexis (United States)6
已完成
1 期
A Phase 1, Single-Center, Open-label Study to Evaluate the Pharmacokinetics of PRN1008 in Healthy Male and Female VolunteersInflammatory and Immune System - Autoimmune diseasesSystemic Lupus ErythematosusRheumatoid ArthritisInflammatory Bowel DiseaseACTRN12615000614594Clinical Network Services (CNS) Pty Ltd12
已完成
1 期
A Phase 1, Single-Center, Open-label Study to Evaluate the Safety and Pharmacokinetics of Two Tablet Formulations of PRN1008Rheumatoid ArthritisACTRN12616001557426Principia Biopharma Australia Pty Ltd14